MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
– Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth – Efficacy and safety data of pelabresib for potential treatment improvement in myelofibrosis presented at EHA Congress 2022 – Entered into collaboration with Pfizer and Incyte for a combination … [Read more…]
